El Segundo, CA – March 8, 2018 – BioDiscovery, Inc., a leader in innovative genomic data analysis software solutions announced today that BioDiscovery and Thermo Fisher Scientific have formed a partnership creating an assay plus analysis cancer research package with Nexus Express for OncoScan™ software for Thermo Fisher’s Cancer Research portfolio. BioDiscovery initially began the partnership three years ago with Affymetrix, Inc. (before its acquisition by Thermo Fisher) and due to the success of the partnership at enabling cancer researchers to have access to high quality assay plus software, the two companies have elected to continue the partnership.BioDiscovery, a leader in copy number analysis software, created a new tailored software solution (Nexus Express for OncoScan) for copy number detection and downstream analysis for the OncoScan™ CNV Assay. The assay plus software solution allows researchers performing solid tumor analysis a high-quality, complete, end-to-end solution from raw data to discovery for difficult FFPE samples. The data are analyzed in the powerful software with rich, interactive visualization and robust statistical tools for downstream analysis of single samples as well as large data cohorts.
“Numerous researchers across the globe have relied on our flagship Nexus Copy Number product as well as the Nexus Express for OncoScan software product for quick and robust analysis of genomic data,” said Dr. Soheil Shams, Founder, BioDiscovery. “Nexus Express for OncoScan provides researchers rapid and complete analysis of OncoScan samples with detection of copy number and allelic events combined with somatic mutations and with statistical analysis tools to compare between sub-groups, perform survival analysis, integrate gene expression results and more. The partnership with Thermo Fisher is a great example of the success we’ve had supporting OEM customers. We have seen a significant increase in OEM customers due to our software development capabilities. Our goal is to ensure our partners have a strategic advantage against the competition by leveraging our software.”
About BioDiscovery, Inc.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company’s mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care. For more information, visit http://www.biodiscovery.com.